#United States #Morristown #Oncology Treatment #Aadi Bioscience #KAKEN INVESTMENTS

Aadi Bioscience Reports Full Approval of Proposals at Stockholder Meeting

On March 3rd, 2025, Aadi Bioscience, Inc. (NASDAQ: AADI), known for its innovative oncology therapeutics, revealed significant outcomes from their Special Meeting of Stockholders, which was held on February 28, 2025. During this meeting, stockholders overwhelmingly endorsed all proposals presented, marking a critical step for the company’s strategic progress in the oncology field.

Key Proposals Approved

Divestiture Proposal

Among the focal points of the meeting was the Divestiture Proposal, through which Aadi will sell 100% of the outstanding shares of its subsidiary, Aadi Subsidiary, Inc., to KAKEN INVESTMENTS INC. This sale encompasses the FYARRO® program, which focuses on sirolimus protein-bound particles for injectable suspension. The divestiture is expected to streamline Aadi's operations and concentrate its resources on core initiatives that will enhance their focus on high-potential areas of oncology treatment. This strategic move not only signifies a reallocation of resources but also highlights the company’s commitment to maximizing shareholder value.

PIPE Financing Proposal

The meeting also saw the approval of the PIPE Financing Proposal. Under this, Aadi will issue approximately 21,592,000 shares of its common stock at a price of $2.40 per share, in compliance with Nasdaq Listing Rule 5635. Additionally, 20,076,500 pre-funded warrants to purchase shares will also be issued at a price of approximately $2.40 each. This financing round is poised to bolster the company’s cash reserves as it navigates through critical developments in advancing its oncology treatment portfolio.

Equity Plan Increase Proposal

Furthermore, stockholders approved an amendment to the Aadi Bioscience 2021 Equity Incentive Plan, allowing an increase in shares available for issuance by 6,300,000 shares, bringing the total to 8,300,284 shares. Another significant change permits an increase to the annual automatic share reserve increase from 4% to 5%. This modification is aimed at ensuring that Aadi can attract and retain top talent, a necessity in the highly competitive field of biotechnology and pharmaceutical development.

Non-Binding Advisory Vote on Golden Parachutes

In addition, a non-binding advisory vote concerning compensation arrangements for executive officers in relation to the Divestiture proposal was approved. This measure underscores the company’s dedication to transparency and alignment with shareholders when addressing executive compensation, particularly in the context of significant corporate transitions.

Looking Ahead

Following the Special Meeting, final voting results will be disclosed in a Form 8-K filing with the Securities and Exchange Commission (SEC), ensuring comprehensive transparency regarding these pivotal decisions.

Aadi Bioscience is at the forefront of precision oncology, integrating advanced technologies into the treatment of particularly challenging cancer types. This recent round of approvals reflects the company’s commitment to innovative solutions while affirming stockholder support as they navigate future initiatives. For more details regarding Aadi's strategic direction and to stay updated, stakeholders are encouraged to visit their official website at aadibio.com.

As Aadi Bioscience moves forward, its commitment to improving the precision and effectiveness of oncology therapies remains steadfast, demonstrating a powerful vision for transforming how cancer is treated. Stakeholders, investors, and patients alike will be watching closely as the company implements these new strategies and aims for successful outcomes in its ongoing journey to enhance cancer treatment.